June 29, 2023 03:01 PM EDTUpdated 05:07 PM

Updated: BioMarin’s hemophilia A gene therapy Roctavian wins FDA approval after delay and rejection, priced at $2.9M

The FDA approved the first gene therapy to treat the genetic bleeding disorder hemophilia A on Thursday, capping a turbulent regulatory …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Up­dat­ed: Bio­Marin’s he­mo­phil­ia A gene ther­a­py Roc­ta­vian wins FDA ap­proval af­ter de­lay and re­jec­tion, priced at $2.9M